"....Outset Medical, based in San Jose, California, seeks to empower dialysis patients through technology.
Outset’s Tablo device aims to transform dialysis in the way ATMs have done for banking and self-checkout kiosks for grocery shopping.
The Tablo, which resembles a dormitory refrigerator, breaks down the act of dialyzing in simple steps. Patients and/or technicians are given prompts on a video screen. Concentrates required for the session come in modules easily installed into the machine, which in turn can be connected to a sink faucet, bypassing the need to purify the water supply. There is also no need for 'stringing' — the need to push tubing throughout the device much in the same way an old film projector is threaded. Patients can hook themselves up in about 10 minutes and as quickly as six minutes, according to Outset CEO Leslie Trigg."
Read More: http://catalyst.nejm.org/the-big-business-of-dialysis-care/
Via: NEJM Catalyst
CAMBRIDGE, Mass., May 18, 2016 (GLOBE NEWSWIRE) -- Metabolix, Inc. (NASDAQ:MBLX) announced today that it has entered into an amendment to its license agreement with Tepha, Inc., a Lexington, Massachusetts based medical device company that licenses Metabolix PHA biopolymer technology for use in certain medical applications. The amendment calls for a $2.0 million lump sum payment to Metabolix. In exchange, Metabolix agreed to forgo future royalties under its existing license agreement with Tepha and to provide two additional Metabolix production strains and related intellectual property to Tepha for use in the production of Tepha's medical devices.
NEW YORK, New York, May 5, 2016 — Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced that the Company has launched a new website, CiraraStories.com, which will feature people afflicted by this devastating condition – patients, their families, and the medical professionals who care for them.
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
REDWOOD CITY, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
REDWOOD CITY, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
Silk Road Medical Announces FDA 510(k) Clearance and First Patients Treated in the US with the Next Generation ENROUTE® Transcarotid Neuroprotection System
Via: Yahoo! Finance
System Designed Specifically for Novel TransCarotid Artery Revascularization (TCAR) Procedure to be Immediately Launched in the United States
NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing lifesaving hospital-based treatment to people affected by central nervous system (CNS) related edema, today announced the appointment of Dr. Thomas R. Zimmerman Jr. as its Vice President, Medical Affairs.
Via: The New York Times
WASHINGTON — The Obama administration plans on Wednesday to propose expanding Medicare to cover programs to prevent diabetes among millions of people at high risk of developing the disease, marking the sixth anniversary of the Affordable Care Act with the prospect of a new benefit, federal officials said.
Via: Omada Health
HHS Secretary Announces Expansion of Reimbursement for CDC-Recognized Diabetes Prevention Programs like Omada Health
Monteris Medical has opened its new headquarters facility in Plymouth.